Annual report pursuant to Section 13 and 15(d)

Accrued Expenses

v3.19.1
Accrued Expenses
12 Months Ended
Dec. 31, 2018
Payables and Accruals [Abstract]  
Accrued Expenses

8. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

    December 31,  
    2018     2017  
Accrued clinical operations and trials costs   $ 4,914,881     $ 2,003,799  
Accrued product development costs     2,222,093       1,255,439  
Accrued compensation     2,253,621       1,335,672  
Accrued other     460,596       146,609  
Total   $ 9,851,191     $ 4,741,519